Loading
Life sciences · Journal article
Reports of Practical Oncology & Radiotherapy · October 28, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
This review discusses contemporary dose escalation strategies in unfavourable intermediate- and high-risk localised prostate cancer treated with external beam radiotherapy. It provides a clinically oriented comparison of three principal boost modalities: brachytherapy boost, stereotactic body radiotherapy (SBRT) boost and focal boosting of dominant intraprostatic lesions. The radiobiological rationale, key dosimetric characteristics and most important prospective and randomised clinical data are summarised to clarify how each approach affects biochemical control, toxicity and long-term outcomes. The review further outlines anatomical, functional and disease-related factors that influence boost selection, highlighting typical indications and relative contraindications for brachytherapy, SBRT and focal boosts. Particular emphasis is placed on patient selection in routine practice, integration with androgen-deprivation therapy and nodal irradiation, as well as logistical and resource considerations that affect real-world implementation. Remaining evidence gaps, including the need for head-to-head comparisons between boost techniques and for data on combinations with modern systemic treatment intensification, are also discussed. Overall, the article is primarily addressed to clinicians involved in prostate radiotherapy planning and decision-making, but may also be of interest to researchers developing future dose-escalation and personalisation strategies.